Medical Doctor Program year 2024 Reported 2020–2024 Source: CMS Open Payments, 2026 publication

Adam Winters

Gastroenterology Biddeford, ME Medical Doctor

NPI 1700270352 CMS profile 8803088

9 Healthcare Dr Ste 202, Biddeford, ME 04005

Open in the dashboard

General payments

$254

3 records reported · program years 2020–2024

Research payments

$0

Paid to them · None reported · program years 2020–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Adam Winters of Biddeford, ME is reported in the CMS Open Payments database as having received $254 across 3 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 17th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $122 1
2023 General $109 1
2020 General $23 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Adam Winters
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Adam Winters were reported at $0. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Adam Winters Gastroenterology median Middle half National median
2019 $0 $417 $126–$1,100 $163
2020 $23 $224 $74–$624 $114
2021 $0 $352 $106–$1,054 $132
2022 $0 $448 $129–$1,270 $149
2023 $109 $533 $150–$1,390 $160
2024 $122 $605 $160–$1,606 $164
2025 $0 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2020–2024
  1. Mallinckrodt Hospital Products Inc. $122 1 payment
  2. Gilead Sciences, Inc. $109 1 payment
  3. AbbVie, Inc. $23 1 payment

Every payment, record by record

What the payments were for General payments · program years 2020–2024
  1. Food and Beverage $254 3 payments
Products named General payments · program years 2020–2024
  1. TERLIVAZ $122 1 payment
  2. HUMIRA $23 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

517

Median for Gastroenterology: 569

Drug cost

$72,264

Median for Gastroenterology: $104,976

Branded share of claims

13.7%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Tacrolimus Generic 136 $20,120
Prograf Tacrolimus Brand 14 $18,711
Sirolimus Generic 13 $11,380
Mycophenolate Mofetil Generic 40 $9,347
Ursodiol Generic 66 $6,274
Cyclosporine Modified Cyclosporine, Modified Brand 37 $3,217
Entecavir Generic 27 $2,186
Pantoprazole Sodium Generic 52 $211
Amlodipine Besylate Generic 22 $202
Nifedipine Er Nifedipine Brand 20 $169

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 23 billing codes

Paid by Medicare

$27,524

Medicare's payments for the services billed

Medicare patients

149

Average age 67

Services billed

338

71 women, 78 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 50%
Chronic kidney disease 50%
Arthritis 46%
Ischemic heart disease 38%
Heart failure 34%
Depression 33%
Atrial fibrillation 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

3 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Maine

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record